RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Aptorum Group (NASDAQ:APM) has priced its public offering of 2,769,231 Class A ordinary shares and warrants to purchase up to same number of Class A shares, at a combined price of $3.25/share and related warrant, for expected gross proceeds of ~$9M.
The five-year warrants have an exercise price of $3.25/share.
NAI500 seeks to provide the most pressing investment knowledge to its readers. On October 7 and 8, NAI500 is hosting a FREE VIRTUAL EVENT focusing on the rapidly growing mining sector. Learn about Gold and Precious Metals Exploration, Battery Metals and much more by registering here.
Net proceeds will be used to conduct further analyses of SACT-1 and ALS-4, for development of pipeline candiadtes into their respective clinical phases, for working capital and general corporate purposes.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Yesterday’s close was $4.76. Shares down 4% after-hours.
Pfizer (NYSE:PFE) subsidiaries will make a $200M equity investment in CStone Pharmaceuticals (OTCPK:CSPHF) for the development and commercialization of latter’s sugemalimab (CS1001, PD-L1 antibody) in mainland China.
Pfizer obtains exclusive commercialization rights to sugemalimab in mainland China, while CStone continues to lead clinical development and regulatory strategy for five selected indications.
CStone to receive up to $280M in milestone payments for sugemalimab and additional tiered royalties.
Pfizer will invest $200M, consisting of 115,928,803 CStone shares at a price of $1.725/share (~HK$13.37/share). As a result, PFE will hold a 9.90% stake in CStone.
Both the companies may pursue on a selected basis joint in-licensing arrangements for additional oncology assets for the Greater China market.
CStone will host a live webcast at 11:00am (Hong Kong time) on September 30.
Moderna (NASDAQ:MRNA) +3.5% after-hours as results from a Phase 1 study shows its mRNA-1273 coronavirus vaccine candidate is well-tolerated and generates a strong immune response in older adults.
The vaccine, which is co-developed by researchers at Moderna and the National Institute of Allergy and Infectious Diseases, produced virus neutralizing antibodies at levels similar to those seen in younger adults, with side effects roughly equal to high-dose flu shots, according to a study published in the New England Journal of Medicine.
The findings are reassuring because immunity tends to weaken with age, Dr. Evan Anderson, one of the study’s lead researchers from Emory University, tells Reuters.
Swiss contract manufacturer Lonza said today it is confident that its plants in the U.S. and Switzerland will be ready to produce commercial quantities of mRNA-1273, expected to total 300M doses annually.
Noted short seller Citron Research sees 83% downside risk (price target = $2) in Inovio Pharmaceuticals (INO -4.9%) on the heels of the FDA’s partial clinical hold on its planned Phase 2/3 clinical trial evaluating COVID-19 vaccine candidate INO-4800 and the Cellectra 2000 delivery device.
Citron believes the issue is Chemistry, Manufacturing and Controls data. Specifically, the company switched manufacturers mid-development which prompted the agency to reassess the processes and procedures to ensure that the drug substance is unchanged.
Citron also reminds investors that the company has no track record of advancing products into the marketplace and it lags all of the major vaccine developers.
Quant rating is Neutral.
Aimed a supporting the National Health Service’s needs for COVID-19 testing, Novacyt (OTC:NVYTF) inks a new supply contract with the U.K. Department of Health and Social Care (DHSC) for its q16 and q32 Rapid-PCR instrument platforms, exsig COVID-19 Direct kits and genesig SARS-CoV-2 Winterplex kits. It is the second major deal awarded by DHSC to its molecular diagnostics unit, Primerdesign.
Under the terms of the two-phase contract, Primerdesign will supply product to the DHSC for up to six months. Phase one, involving the immediate deployment of 300 PCR instruments and related kit, has an initial term of 14 weeks with an optional extension for an addition 10 weeks, with a minimum value of £150 million for the first 14 weeks.
An optional phase two allows for the deployment of an additional 700 PCR units, related kit and additional COVID-19 products where required.
